#USA #MedTech #Charlottesville #RIVANNA #Accuro

RIVANNA Nominated for MedTech Scale-Up of the Year Award

Charlottesville, VA — RIVANNA®, known for its advancements in AI-powered clinical decision-support solutions, proudly announces its nomination for the prestigious _MedTech Scale-Up of the Year_ at the MedTech World Awards 2026. This distinguished recognition places RIVANNA alongside leading growth-stage medical technology firms making significant strides in commercial operations and innovation.

The public voting phase for this award is now open until May 8, 2026, and the winners will be revealed at the inaugural North American Awards Gala, set to occur on May 11, 2026, at the Hilton West Palm Beach in Florida. This marks a pivotal moment for the MedTech World Awards, being the first time they have been held in the United States.

Celebrating Growth in MedTech

The _MedTech Scale-Up of the Year_ category is designed to highlight companies like RIVANNA that have successfully scaled their business operations, expanding partnerships and adoption rates in the competitive medical tech landscape. Nominees undergo a rigorous selection process by the MedTech World Steering Committee, culminating in a voting mechanism that includes expert evaluators as well as public input from the global MedTech community.

Dr. Will Mauldin, RIVANNA's Co-founder and CEO, expressed his pride regarding the nomination: "We have built RIVANNA on validation earned from the most rigorous technical buyers in healthcare. Our success translates into FDA-cleared products, complemented by commercial programs that seamlessly integrate into clinical workflows. This nomination serves as a testament to our approach and our dedicated team." This sentiment underscores the significance of the nomination as both an acknowledgment of past achievements and motivation for RIVANNA to elevate its impact in the healthcare sector.

Recent Achievements

RIVANNA’s recent achievements underscore its robust growth trajectory and innovative spirit:

• - October 2025: Named a finalist in MedTech Innovator's 2025 Early-Stage Grand Prize competition, representing the top 4% of medtech innovations worldwide among nearly 1,500 applicants.
• - December 2025: Received FDA’s 510(k) clearance for its _Accuro® 3S Needle Guide Kit_, a notable expansion of its existing device capabilities.
• - April 2026: Published peer-reviewed findings in the _Journal of Emergency Medicine_ showcasing the ease of use for non-physicians in acquiring diagnostic-quality scans with the _Accuro® XV_ system following just one hour of training.
• - May 2026: Secured FDA clearance for the _Accuro® XV Diagnostic Ultrasound System_ specifically for musculoskeletal imaging, paving the way for commercial distributions in numerous clinical settings.

Along with these triumphs, RIVANNA boasts an expanding clinical program that encompasses eight sites across the nation, with over 1,500 patients actively engaged in exploring the benefits of its innovative solutions.

The Importance of Public Support

As the award nomination progresses, RIVANNA encourages members of the MedTech community to support its candidacy through public voting, available via the official voting page. Each vote signifies not only recognition of RIVANNA's accomplishments but also a collective endorsement of innovation within the healthcare technology field.

The 2026 MedTech World Awards, powered by Blue Goat Cyber, will encapsulate a celebration of growth, innovation, and leadership in the medical technology arena. Utilization of advanced AI and proprietary clinical datasets by RIVANNA is setting new standards in precision and accessibility in healthcare, affirming its role as a key player in transformative medical solutions.

About RIVANNA

Founded in Charlottesville, Virginia, RIVANNA® specializes in creating cutting-edge clinical decision-support technologies. Their offerings are built on strong regulatory achievements and clinical validations, with a portfolio that includes the _Accuro®_ platform, which is designed to automate complex anatomical analyses at the point of care. The company has secured over 100 patents and operates an FDA-registered manufacturing facility, highlighting its commitment to quality and innovation in the medical field. Explore more about their pioneering efforts at rivannamedical.com.